Literature DB >> 2536815

Epidemiologic correlates of cervical neoplasia and risk of human papillomavirus infection in asymptomatic women in Brazil.

L L Villa1, E L Franco.   

Abstract

To investigate whether the epidemiologic correlates of cervical cancer are predictors of infection with genital human papillomavirus (HPV), we performed a prevalence survey in two metropolitan areas of Brazil, Recife and São Paulo. The data records of four randomly selected HPV-negative women were matched on the basis of age, clinic, and admission period with those of each of 136 patients with positive HPV DNA hybridizations. Anal intercourse [prevalence rate ratio (PRR) = 1.7] and current pregnancy (PRR = 2.3) were the only variables associated with HPV 6/11 infection (P less than .10). Only the frequency of gynecologic consultations was associated (negatively) with risk of HPV 16/18 infection (P = .0175). Our data failed to provide evidence for the existence of shared risk factors for genital HPV infection and cervical cancer. The frequency of mixed HPV infections was 13 times higher than expected, a finding suggestive of the existence of additional determinants of HPV infection not akin to the general behavioral characteristics of women that are probed in the study.

Entities:  

Mesh:

Year:  1989        PMID: 2536815     DOI: 10.1093/jnci/81.5.332

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  18 in total

1.  Prevalence of low and high risk human papillomavirus types in cervical cells from Hong Kong pregnant Chinese using filter in situ hybridization.

Authors:  E W Ip; R J Collins; A N Cheung; G Srivastava
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

Review 2.  Report of a National Workshop on Screening for Cancer of the Cervix.

Authors:  A B Miller; G Anderson; J Brisson; J Laidlaw; N Le Pitre; P Malcolmson; P Mirwaldt; G Stuart; W Sullivan
Journal:  CMAJ       Date:  1991-11-15       Impact factor: 8.262

3.  Sexual risk behavior in women with cervical human papillomavirus infection.

Authors:  B Sikström; D Hellberg; S Nilsson; C Brihmer; P A Mårdh
Journal:  Arch Sex Behav       Date:  1996-08

4.  Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions.

Authors:  Talía Malagón; Philippe Lemieux-Mellouki; Jean-François Laprise; Marc Brisson
Journal:  Am J Epidemiol       Date:  2016-12-07       Impact factor: 4.897

Review 5.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

6.  Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA.

Authors:  A O Olsen; J Dillner; K Gjøen; P Magnus
Journal:  Genitourin Med       Date:  1997-04

Review 7.  Pathogenesis of genital HPV infection.

Authors:  A Schneider
Journal:  Genitourin Med       Date:  1993-06

8.  Smoking, alcohol, sexual behaviour and drug use in women with cervical human papillomavirus infection.

Authors:  B Sikström; D Hellberg; S Nilsson; P A Mårdh
Journal:  Arch Gynecol Obstet       Date:  1995       Impact factor: 2.344

9.  Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination.

Authors:  Joseph E Tota; Agnihotram V Ramanakumar; Mengzhu Jiang; Joakim Dillner; Stephen D Walter; Jay S Kaufman; François Coutlée; Luisa L Villa; Eduardo L Franco
Journal:  Am J Epidemiol       Date:  2013-05-09       Impact factor: 4.897

10.  Molecular variants of human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind.

Authors:  S Y Chan; L Ho; C K Ong; V Chow; B Drescher; M Dürst; J ter Meulen; L Villa; J Luande; H N Mgaya
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.